Regulatory filing 📈 Stocks 🌍 United States

MetaVia Completes Phase 1 Study Visit for DA-1726 Liver Disease Candidate

MetaVia advances its DA-1726 liver disease program after completing Phase 1 Part 3A, with full data expected in Q1 2027 and a Phase 2 trial planned for the second half of 2027.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: MTVA ↑ 4/10 (60% confidence).

📊 Affected Assets (1)

MTVA
Bullish 🤖 60%
📅 Short-term 🌍 US · Explicit

MetaVia reports the last patient completed the extended 24-week Phase 1 visit for DA-1726 at the 48 mg dose and cites previously reported Part 3B interim results: a 68.1% placebo-adjusted liver fat reduction and 13.5% placebo-adjusted weight loss at Day 109, with all five steatosis patients falling below 5% MRI-PDFF. These are hard, quantified data points supporting the planned 48-week Phase 2 in MetALD/ALD in the second half of 2027. However, the key interim figures were already released, so the new information is mainly trial progress and timelines, which limits the incremental price effect

Catalysts
  • ▲ Completion of last patient visit in the extended 24-week Phase 1 Part 3A study (announced November 17, 2026)
  • ▲ Full data from Parts 3A and 3B expected in the first quarter of 2027
Risk Factors
  • ▼ Results are preliminary safety and tolerability observations, not full efficacy data
  • ▼ Full Parts 3A and 3B results are only due in Q1 2027 and could differ from interim figures

🧭 Full analysis of these assets

🎯 Key Takeaways

  • The last patient completed the extended 24-week Phase 1 Part 3A study of DA-1726 at a 48 mg dose.
  • Interim Part 3B results showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss at Day 109.
  • Full data from Parts 3A and 3B is expected in the first quarter of 2027.
  • MetaVia plans to initiate a 48-week, non-biopsy Phase 2 study in up to 150 patients with MetALD and ALD in the second half of 2027.

📝 Executive Summary

MetaVia Inc. announced the completion of the final patient visit for its extended 24-week Phase 1 Part 3A study of DA-1726. The company is preparing for a 48-week Phase 2 trial in MetALD and ALD patients, targeted for the second half of 2027, following positive interim data showing significant reductions in liver fat and body weight.

❓ FAQ

What new clinical results were announced?

The last patient completed the final visit of the extended 24-week Phase 1 Part 3A study of DA-1726 at 48 mg weekly. The company also highlighted its Part 3B interim analysis showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss after 16 weeks.

When will more data come?

Full data from Parts 3A and 3B is expected in the first quarter of 2027, and a 48-week Phase 2 study in up to 150 patients with MetALD and ALD is targeted to begin in the second half of 2027.